Correspondence on Letter regarding "Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study"

[...]as the authors point out [3], it was not possible to determine whether MASLD patients had a clearly higher incidence or fatality rate of CVD than non-MASLD patients. [...]although a sub-analysis of the Le et al. Recent studies have demonstrated the usefulness of the diabetes mellitus drugs sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) for treatment of MASLD. [...]their potential as therapeutic agents is expanding [10-12], and in actual clinical practice, there are many MASH/MASLD patients already taking SGLT-2i and GLP-1RA. The world is therefore entering an era in which we will likely see a cure for MASH/MASLD. [...]with continuing advances in noninvasive diagnostic methods, we expect the need for liver biopsy to decrease in the future. Abbreviations NAFLD, nonalcoholic fatty liver disease; CLIONE, Clinical Outcome Nonalcoholic Fatty Liver Disease; MASLD, metabolic dysfunction-associated steatotic liver disease; CVD, cardiovascular disease; NASH–CRN, Nonalcoholic Steatohepatitis Clinical Research Network; BMI, body mass index; SLD, steatotic liver disease; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; Hs-CRP, high-sensitivity C-reactive protein; SGLT-2i, sodium-glucose cotransporter-2 inhibitors; GLP-1RA, glucagon-like peptide-1 receptor agonists 1.